| Literature DB >> 30509888 |
Damien Gulliver1, Eryn Werry1, Tristan A Reekie2, Timothy A Katte2, William Jorgensen2, Michael Kassiou3.
Abstract
Deficits in social behavioral domains, such as interpersonal communication, emotion recognition, and empathy, are a characteristic symptom in several neuropsychiatric disorders, including schizophrenia and autism spectrum disorder (ASD). The neuropeptide oxytocin (OT) has emerged as a key regulator of diverse social behaviors in vertebrates and, thus, has been identified as a potential therapeutic target for improving social dysfunction. In recent years, the field of OT research has seen an explosion of scientific inquiry, producing a more comprehensive picture of oxytocinergic signaling and the pathways that regulate its release and degradation in the brain. In this review, we provide an analysis of how this information is being exploited to accelerate the discovery of novel oxytocinergic therapeutics.Entities:
Keywords: drug development; neuropsychiatric disease; oxytocin; social cognition
Mesh:
Substances:
Year: 2018 PMID: 30509888 DOI: 10.1016/j.tips.2018.11.001
Source DB: PubMed Journal: Trends Pharmacol Sci ISSN: 0165-6147 Impact factor: 14.819